TrialJournal of clinical pharmacology2025

Osimertinib Cost Minimization in Non-Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat.

Niels Westra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.